Xeris Biopharma Holdings Inc (NASDAQ:XERS) has a beta value of 0.69 and has seen 1.28 million shares traded in the recent trading session. The company, currently valued at $754.31M, closed the recent trade at $4.90 per share which meant it lost -$0.11 on the day or -2.20% during that session. The XERS stock price is -23.88% off its 52-week high price of $6.07 and 64.69% above the 52-week low of $1.73.
The consensus among analysts is that Xeris Biopharma Holdings Inc (XERS) is Buy stock at the moment, with a recommendation rating of 1.33. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 3 have rated it as a Hold, with 3 advising it as a Buy. 0 have rated the stock as Underweight.
Xeris Biopharma Holdings Inc (NASDAQ:XERS) trade information
Sporting -2.20% in the red today, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the XERS stock price touched $4.90 or saw a rise of 7.2%. Year-to-date, Xeris Biopharma Holdings Inc shares have moved 44.54%, while the 5-day performance has seen it change 5.60%. Over the past 30 days, the shares of Xeris Biopharma Holdings Inc (NASDAQ:XERS) have changed 24.05%.
Wall Street analysts have a consensus price target for the stock at $4, which means that the shares’ value could drop -22.5% from the levels at last check today.. The projected low price target is $4.0 while the price target rests at a high of $4.0. In that case, then, we find that the latest price level in today’s session is 18.37% off the targeted high while a plunge would see the stock lose 18.37% from the levels at last check today..
Xeris Biopharma Holdings Inc (XERS) estimates and forecasts
The company’s shares have gained 46.71% over the past 6 months.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 40.01% over the past 5 years.
XERS Dividends
Xeris Biopharma Holdings Inc is expected to release its next earnings report in June this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Xeris Biopharma Holdings Inc (NASDAQ:XERS)’s Major holders
The top two institutional holders are BLACKROCK INC. with over 10.33 million shares worth more than $23.25 million. As of 2024-06-30, BLACKROCK INC. held 6.9649% of shares outstanding.
The other major institutional holder is VANGUARD GROUP INC, with the holding of over 7.66 million shares as of 2024-06-30. The firm’s total holdings are worth over $17.23 million and represent 5.1615% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF . As of Dec 31, 2024 , the former fund manager holds about 2.70% shares in the company for having 4.22 shares of worth $20.39 million while later fund manager owns 3.71 shares of worth $17.91 million as of Mar 31, 2025 , which makes it owner of about 2.37% of company’s outstanding stock.
